Mechanism of oestrogen and progesterone effects on lipid and carbohydrate metabolism: alteration in the insulin: glucagon molar ratio and hepatic enzyme activity.
As in women receiving oestrogens the administration of 17beta-oestradiol to ovariectomized female rats caused a rise in fasting plasma triglycerides and a fall in plasma glucose. Progesterone, on the other hand, had no significant effects. In the oestradiol treated rats, the portal vein basal insulin levels were slightly reduced. Oestradiol, however, had a marked suppressive effect on the alpha cells of the pancreas resulting in a greater reduction in basal glucagon and impaired glucagon response to alanine infusions. The relative insulin to glucagon (I/G) molar concentration ratio in portal vein blood was increased. Oestradiol also produced a dose dependent increase in the activity of the liver lipogenic enzymes, acetyl CoA carboxylase and fatty acid synthetase. On the other hand, the activity of the gluconeogenic rate limiting enzyme phosphoenol-pyruvate carboxykinase (PEPCK) was inhibited. The cross-over pattern of gluconeogenic intermediates confirmed inhibition of gluconeogenesis at this step, an effect which is similar to that induced by relative insulin 'excess'. Progesterone produced an increase in the portal vein insulin concentrations. Both the basal and the alanine-stimulated glucagon levels were also increased. The I/G molar ratio in portal vein blood of progesterone treated rats remained unaltered and the hepatic lipogenic and gluconeogenic enzyme activities were similar to control animals. These data suggest that insulin activity is increased relative to glucagon in the liver of oestradiol-treated rats due to the rise in portal vein I/G ratio. The changes in liver lipogenic and gluconeogenic enzymes and the alterations in fasting plasma triglycerides and glucose in response to oestrogens could be secondary to this effect.
D000105:Acetyl Coenzyme A; D000103:Acetyl-CoA Carboxylase / Q000378:metabolism; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D002369:Castration; D004958:Estradiol / Q000008:administration & dosage / Q000494:pharmacology*; D064429:Fatty Acid Synthases / Q000378:metabolism; D005227:Fatty Acids; D005260:Female; D005934:Glucagon / Q000097:blood*; D005943:Gluconeogenesis / Q000187:drug effects; D007328:Insulin / Q000097:blood*; D050356:Lipid Metabolism; D008099:Liver / Q000378:metabolism*; D010728:Phosphoenolpyruvate; D010729:Phosphoenolpyruvate Carboxykinase (GTP) / Q000378:metabolism; D011374:Progesterone / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D014280:Triglycerides / Q000097:blood*
D001786:Blood Glucose; D005227:Fatty Acids; D007328:Insulin; D014280:Triglycerides; D011374:Progesterone; D004958:Estradiol; D000105:Acetyl Coenzyme A; D010728:Phosphoenolpyruvate; D005934:Glucagon; D064429:Fatty Acid Synthases; D010729:Phosphoenolpyruvate Carboxykinase (GTP); D000103:Acetyl-CoA Carboxylase